PURPOSE: We have demonstrated that (-)-gossypol-enriched cottonseed oil [(-)-GPCSO] can down-regulate Bcl-2 expression in MCF-7 and primary cultured human breast cancer epithelial cells (PCHBCECs). However, this agent has not been evaluated in vivo due to its limited solubility. We aimed to develop liposomes containing (-)-GPCSO to suppress Bcl-2/Bcl-xL expression. METHODS: (-)-GPCSO liposomes were prepared and evaluated for effects on breast cancer cell viability, MDA-MB-231 xenograft tumor growth, cellular Bcl-2 and Bcl-xL mRNA levels, and chemosensitivity to paclitaxel. RESULTS: (-)-GPCSO liposomes prepared had excellent stability. Cytotoxicity of (-)-GPCSO liposomes was significantly reduced compared to (-)-GPCSO in culture medium. Bcl-2 and Bcl-xL mRNA expression was down-regulated by (-)-GPCSO in culture medium or (-)-GPCSO liposomes in MDA-MB-231 cells. In PCHBCECs, Bcl-2 and Bcl-xL expression were down-regulated by (-)-GPCSO liposomes. (-)-GPCSO in culture medium induced only a mild reduction in Bcl-xL. In the MDA-MB-231 xenograft tumor model, (-)-GPCSO liposomes exhibited tumor-suppressive activity and significantly reduced intratumoral Bcl-2 and Bcl-xL expression. Cytotoxicity of paclitaxel was increased by pretreatment with (-)-GPCSO liposomes in MDA-MB-231 and PCHBCECs. CONCLUSIONS: Findings suggest that (-)-GPCSO liposomes warrant continued investigation as a chemosensitizer for breast cancers exhibiting Bcl-2-/Bcl-xL-mediated drug resistance.
PURPOSE: We have demonstrated that (-)-gossypol-enriched cottonseed oil [(-)-GPCSO] can down-regulate Bcl-2 expression in MCF-7 and primary cultured humanbreast cancer epithelial cells (PCHBCECs). However, this agent has not been evaluated in vivo due to its limited solubility. We aimed to develop liposomes containing (-)-GPCSO to suppress Bcl-2/Bcl-xL expression. METHODS:(-)-GPCSO liposomes were prepared and evaluated for effects on breast cancer cell viability, MDA-MB-231 xenograft tumor growth, cellular Bcl-2 and Bcl-xL mRNA levels, and chemosensitivity to paclitaxel. RESULTS:(-)-GPCSO liposomes prepared had excellent stability. Cytotoxicity of (-)-GPCSO liposomes was significantly reduced compared to (-)-GPCSO in culture medium. Bcl-2 and Bcl-xL mRNA expression was down-regulated by (-)-GPCSO in culture medium or (-)-GPCSO liposomes in MDA-MB-231 cells. In PCHBCECs, Bcl-2 and Bcl-xL expression were down-regulated by (-)-GPCSO liposomes. (-)-GPCSO in culture medium induced only a mild reduction in Bcl-xL. In the MDA-MB-231 xenograft tumor model, (-)-GPCSO liposomes exhibited tumor-suppressive activity and significantly reduced intratumoral Bcl-2 and Bcl-xL expression. Cytotoxicity of paclitaxel was increased by pretreatment with (-)-GPCSO liposomes in MDA-MB-231 and PCHBCECs. CONCLUSIONS: Findings suggest that (-)-GPCSO liposomes warrant continued investigation as a chemosensitizer for breast cancers exhibiting Bcl-2-/Bcl-xL-mediated drug resistance.
Authors: B Elenbaas; L Spirio; F Koerner; M D Fleming; D B Zimonjic; J L Donaher; N C Popescu; W C Hahn; R A Weinberg Journal: Genes Dev Date: 2001-01-01 Impact factor: 11.361
Authors: Suling Liu; Samuel K Kulp; Yasuro Sugimoto; Jiahua Jiang; Hsiang-Lin Chang; Michael K Dowd; Peter Wan; Young C Lin Journal: Anticancer Res Date: 2002 Jan-Feb Impact factor: 2.480
Authors: T Safra; F Muggia; S Jeffers; D D Tsao-Wei; S Groshen; O Lyass; R Henderson; G Berry; A Gabizon Journal: Ann Oncol Date: 2000-08 Impact factor: 32.976
Authors: N Hiraoka; Y Ino; S Sekine; H Tsuda; K Shimada; T Kosuge; J Zavada; M Yoshida; K Yamada; T Koyama; Y Kanai Journal: Br J Cancer Date: 2010-08-24 Impact factor: 7.640
Authors: Robert Matthew Kottmann; Emma Trawick; Jennifer L Judge; Lindsay A Wahl; Amali P Epa; Kristina M Owens; Thomas H Thatcher; Richard P Phipps; Patricia J Sime Journal: Am J Physiol Lung Cell Mol Physiol Date: 2015-09-25 Impact factor: 5.464
Authors: Jennifer L Judge; David J Nagel; Kristina M Owens; Ashley Rackow; Richard P Phipps; Patricia J Sime; R M Kottmann Journal: PLoS One Date: 2018-05-24 Impact factor: 3.240
Authors: Olga Renner; Mascha Mayer; Christian Leischner; Markus Burkard; Alexander Berger; Ulrich M Lauer; Sascha Venturelli; Stephan C Bischoff Journal: Pharmaceuticals (Basel) Date: 2022-01-26